Integrated Biopharma Files 8-K on Operations and Financials
Ticker: INBP · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1016504
| Field | Detail |
|---|---|
| Company | Integrated Biopharma Inc (INBP) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, operations
TL;DR
IBP filed an 8-K for operational and financial updates. Check for details.
AI Summary
Integrated Biopharma, Inc. filed an 8-K on September 23, 2024, reporting on events that occurred on September 20, 2024. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. Specific financial details or operational updates were not detailed in the provided header information.
Why It Matters
This 8-K filing signals that Integrated Biopharma, Inc. is providing updated information to the SEC regarding its financial condition and operational results, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for reporting operational and financial information, not indicating any immediate or significant adverse events.
Key Players & Entities
- INTEGRATED BIOPHARMA INC (company) — Registrant
- September 20, 2024 (date) — Date of earliest event reported
- September 23, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 22-2407475 (identifier) — I.R.S. Employer Identification No.
- 001-31668 (identifier) — Commission File Number
FAQ
What specific events or financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not present in the header information.
When was the earliest event reported in this filing?
The earliest event reported was on September 20, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 22-2407475.
What is the Commission File Number for Integrated Biopharma, Inc.?
The Commission File Number is 001-31668.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-09-23 10:51:56
Filing Documents
- inbp20240917_8k.htm (8-K) — 40KB
- ex_725128.htm (EX-99.1) — 74KB
- ibp_logo.jpg (GRAPHIC) — 12KB
- 0001437749-24-029810.txt ( ) — 256KB
- inbp-20240920.xsd (EX-101.SCH) — 3KB
- inbp-20240920_def.xml (EX-101.DEF) — 10KB
- inbp-20240920_lab.xml (EX-101.LAB) — 14KB
- inbp-20240920_pre.xml (EX-101.PRE) — 10KB
- inbp20240917_8k_htm.xml (XML) — 2KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On September 20, 2024, Integrated Biopharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release dated September 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1- EXHIBIT INDEX Exhibit Description 99.1 Press Release dated September 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRATED BIOPHARMA, INC. Date: September 23, 2024 By: /s/ Dina L Masi Dina L. Masi Chief Financial Officer -3-